The spinout has revealed it added approximately $6m to a series A round backed by University of Pennsylvania and IP Group last year, bringing its total size to about $59m.

Carisma Therapeutics, a US-based immunotherapy spinout of University of Pennsylvania, has increased a series A round backed by commercialisation firm IP Group to approximately $59m, Technically Philly reported on Thursday.
The company secured approximately $6m in an extension towards the end of 2018, according to chief executive Steven Kelly. He did not reveal the identity of investors or specify when exactly the extension was secured.
Carisma had achieved a first $53m close for the round in June…